drugset
drugset / Trial / NCT00257881

Study Evaluating Intravenous CMD-193 in Subjects With Advanced Malignant Solid Tumors

NCT00257881 ↗

Phase 1 Terminated 46 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of CMD-193 administered intravenously (IV) to subjects with advanced malignant tumors. The secondary purpose is to obtain preliminary information on the pharmacokinetics and antitumor activity of IV CMD-193.

Timeline

Start
2005-11
Primary completion
—
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CMD-193 Monoclonal antibody — Intravenous

Indications

neoplasm